ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting Highlighting Optimization of Processes for Viral Vector Production


WALTHAM, Mass.--(BUSINESS WIRE)-- ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, today announced four poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting taking place May 16-20, 2023, in Los Angeles, CA. The poster presentations will detail ElevateBio’s research and process development across its lentiviral vector (LVV) and adeno-associated virus (AAV) platforms, optimized to further increase yields and product quality for ease of transition when scaling from research to clinical manufacturing and streamlining product development.

“As we work to meet the growing demand for viral vectors and improve the way cell and gene therapies are developed and manufactured, we’re thrilled to present data showcasing how we’ve optimized process development and manufacturing processes that are scalable, right from the start,” said Michael Paglia, Chief Operating Officer of ElevateBio BaseCamp®. “With our strong scientific foundation and industry-leading expertise, we remain committed to having the best end-to-end development capabilities to rapidly progress cell and gene therapies.”

Presentation Details:
Poster title: Upstream Optimization Paved a Straightforward Path for High Percentage of Full Capsids in AAV6
Abstract #: 424
Session date/time: Wednesday, May 17, 2023: 12:00-2:00 p.m. PT

Poster title: A Robust and Scalable Research Grade Platform Process for AAV6 Production and Purification
Abstract #: 902
Session date/time: Thursday, May 18, 2023: 12:00-2:00 p.m. PT

Poster title: Promoter Triage for Gene Expression & Function Optimization
Abstract #: 1289
Session date/time: Friday, May 19, 2023: 12:00-2:00 p.m. PT

Poster title: Optimization of Nuclease Digestion Unit Operation in a Lentiviral Vector Process for Increased Reduction of DNA Impurities
Abstract/Poster #: 1413
Session date/time: Friday, May 19, 2023: 12:00-2:00 p.m. PT

About ElevateBio:

ElevateBio is a technology-driven company built to power the development of transformative cell and gene therapies today and for many decades to come. The company’s integrated technologies model offers turnkey scale and biotechnological capabilities to power cell and gene therapy processes, programs, and companies to their full potential. The ElevateBio ecosystem combines multiple R&D technology platforms – including Life Edit, a next-generation, full-spectrum gene editing platform; a proprietary induced pluripotent stem cell (iPSC) platform; and an RNA, cell, protein, and vector engineering platform – with BaseCamp®, its end-to-end genetic medicine cGMP manufacturing and process development business, to power the discovery and development of advanced therapeutics.

In addition to enabling a broad breadth of biopharmaceutical companies in the development of their novel cell and gene therapies, ElevateBio is also building a highly innovative pipeline of cellular, genetic, and regenerative medicines. ElevateBio aims to be the dominant engine inside the world’s greatest scientific advancements harnessing human cells and genes to alter disease.

For more information, visit us at www.elevate.bio, or follow ElevateBio on LinkedIn or Twitter.


Catherine Hu

Courtney Heath


Source: ElevateBio, LLC

Back to news